Diagnosis-specific Graded Prognostic Assessment Score is Valid in Patients with Brain Metastases Treated in Routine Clinical Practice in Two European Countries

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2012 Jun 29

PMID 22739735

Citations 19

Authors

Carsten Nieder

Nicolaus H Andratschke

Hans Geinitz

Anca L Grosu

Affiliations

Soon will be listed here.

Abstract

Background: Assessment of cancer- and host-related prognostic factors has a long tradition in patients with brain metastases. In continuation of large-scale studies performed by the Radiation Therapy Oncology Group (RTOG) in the United States, the 4-tiered diagnosis-specific graded prognostic assessment (DS-GPA) score has been developed. It stratifies patients with common primary tumours metastasizing to the brain (malignant melanoma, lung, breast, kidney and gastrointestinal cancers) into subgroups with different prognoses. However, many patients in the DS-GPA study were treated with surgical resection or radiosurgery (SRS). The present multi-institutional analysis examined for the first time whether DS-GPA is a valid score in European patients managed in routine clinical practice.

Material/methods: This was a retrospective analysis of 412 patients with primary malignant melanoma, lung, breast, kidney or gastrointestinal cancers. Survival was evaluated in uni- and multivariate tests.

Results: DS-GPA significantly predicted survival and outperformed initial GPA, a score that is not diagnosis-specific. Median survival by DS-GPA strata (all 412 patients) was 2.7, 3.6, 7.0 and 11.3 months in the 4 groups with 0-1, 1.5-2, 2.5-3 and 3.5-4 points, respectively. The previously published survival data (median 7.2 months for all patients) could not be replicated in this cohort (median 3.6 months).

Conclusions: DS-GPA is a valid prognostic score that might improve shared decision making as well as patient stratification in prospective clinical trials.

Citing Articles

Long-Term Results of Stereotactic Radiotherapy in Patients with at Least 10 Brain Metastases at Diagnosis.

Kinj R, Hottinger A, Bohlen T, Ozsahin M, Vallet V, Dunet V Cancers (Basel). 2024; 16(9).

PMID: 38730695 PMC: 11083879. DOI: 10.3390/cancers16091742.

Treatment of patients with multiple brain metastases by isolated radiosurgery: Toxicity and survival.

de Camargo A, de Mattos M, Kawasaki M, Gomes D, Borges A, de Lima Vazquez V World J Clin Oncol. 2023; 14(10):400-408.

PMID: 37970107 PMC: 10631349. DOI: 10.5306/wjco.v14.i10.400.

Development and adaptations of the Graded Prognostic Assessment (GPA) scale: a systematic review.

Ribeiro L, Bomtempo F, Rocha R, Telles J, Neto E, Figueiredo E Clin Exp Metastasis. 2023; 40(6):445-463.

PMID: 37819546 DOI: 10.1007/s10585-023-10237-3.

Current status and perspectives of interventional clinical trials for brain metastases: analysis of ClinicalTrials.gov.

Tini P, Marampon F, Giraffa M, Bucelli S, Niyazi M, Belka C Radiat Oncol. 2023; 18(1):62.

PMID: 37016421 PMC: 10074717. DOI: 10.1186/s13014-023-02243-2.

Prognostic value of lactate dehydrogenase in non-small cell lung cancer patients with brain metastases: a retrospective cohort study.

Wang S, Lv J, Lv J, Li H, Liu C, Jiang H J Thorac Dis. 2022; 14(11):4468-4481.

PMID: 36524070 PMC: 9745527. DOI: 10.21037/jtd-22-1502.

References

Linskey M, Andrews D, Asher A, Burri S, Kondziolka D, Robinson P . The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2009; 96(1):45-68. PMC: 2808519. DOI: 10.1007/s11060-009-0073-4. View

Nieder C, Mehta M . Prognostic indices for brain metastases--usefulness and challenges. Radiat Oncol. 2009; 4:10. PMC: 2666747. DOI: 10.1186/1748-717X-4-10. View

Gottwald L, Pluta P, Piekarski J, Spych M, Hendzel K, Topczewska-Tylinska K . Long-term survival of endometrioid endometrial cancer patients. Arch Med Sci. 2012; 6(6):937-44. PMC: 3302708. DOI: 10.5114/aoms.2010.19305. View

Rades D, Kueter J, Hornung D, Veninga T, Hanssens P, Schild S . Comparison of stereotactic radiosurgery (SRS) alone and whole brain radiotherapy (WBRT) plus a stereotactic boost (WBRT+SRS) for one to three brain metastases. Strahlenther Onkol. 2008; 184(12):655-62. DOI: 10.1007/s00066-008-1946-8. View

Lorenzoni J, Devriendt D, Massager N, David P, Ruiz S, Vanderlinden B . Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys. 2004; 60(1):218-24. DOI: 10.1016/j.ijrobp.2004.02.017. View

Kalkanis S, Kondziolka D, Gaspar L, Burri S, Asher A, Cobbs C . The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2009; 96(1):33-43. PMC: 2808516. DOI: 10.1007/s11060-009-0061-8. View

Rades D, Kieckebusch S, Haatanen T, Lohynska R, Dunst J, Schild S . Surgical resection followed by whole brain radiotherapy versus whole brain radiotherapy alone for single brain metastasis. Int J Radiat Oncol Biol Phys. 2008; 70(5):1319-24. DOI: 10.1016/j.ijrobp.2007.08.009. View

Suh J, Videtic G, Aref A, Germano I, Goldsmith B, Imperato J . ACR Appropriateness Criteria: single brain metastasis. Curr Probl Cancer. 2010; 34(3):162-74. DOI: 10.1016/j.currproblcancer.2010.04.003. View

Patchell R, Tibbs P, Walsh J, Dempsey R, Maruyama Y, Kryscio R . A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990; 322(8):494-500. DOI: 10.1056/NEJM199002223220802. View

10.

Lagerwaard F, Levendag P, Nowak P, Eijkenboom W, Hanssens P, Schmitz P . Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys. 1999; 43(4):795-803. DOI: 10.1016/s0360-3016(98)00442-8. View

11.

Roehrig S, Wein A, Albrecht H, Konturek P, Reulbach U, Mannlein G . Palliative first-line treatment with weekly high-dose 5-fluorouracil as 24h-infusion and gemcitabine in metastatic pancreatic cancer (UICC IV). Med Sci Monit. 2010; 16(3):CR124-131. View

12.

Andrews D, Scott C, Sperduto P, Flanders A, Gaspar L, Schell M . Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004; 363(9422):1665-72. DOI: 10.1016/S0140-6736(04)16250-8. View

13.

Sperduto P, Berkey B, Gaspar L, Mehta M, Curran W . A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2007; 70(2):510-4. DOI: 10.1016/j.ijrobp.2007.06.074. View

14.

Jenkinson M, Haylock B, Shenoy A, Husband D, Javadpour M . Management of cerebral metastasis: evidence-based approach for surgery, stereotactic radiosurgery and radiotherapy. Eur J Cancer. 2011; 47(5):649-55. DOI: 10.1016/j.ejca.2010.11.033. View

15.

Nieder C, Pawinski A, Molls M . Prediction of short survival in patients with brain metastases based on three different scores: a role for 'triple-negative' status?. Clin Oncol (R Coll Radiol). 2009; 22(1):65-9. DOI: 10.1016/j.clon.2009.08.011. View

16.

Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T . Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997; 37(4):745-51. DOI: 10.1016/s0360-3016(96)00619-0. View

17.

Nieder C, Bremnes R, Andratschke N . Prognostic scores in patients with brain metastases from non-small cell lung cancer. J Thorac Oncol. 2009; 4(11):1337-41. DOI: 10.1097/JTO.0b013e3181b6b6f4. View

18.

Sperduto P, Kased N, Roberge D, Xu Z, Shanley R, Luo X . Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2011; 30(4):419-25. PMC: 3269967. DOI: 10.1200/JCO.2011.38.0527. View

19.

Boxberger F, Albrecht H, Konturek P, Reulbach U, Maennlein G, Meyer T . Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: long-term results of a phase II trial. Med Sci Monit. 2010; 16(2):CR49-55. View

20.

Eigentler T, Figl A, Krex D, Mohr P, Mauch C, Rass K . Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer. 2011; 117(8):1697-703. DOI: 10.1002/cncr.25631. View